Worg Pharmaceuticals
PrivateLast Round
Series D
Extension
Dec 19, 2025
Total Funding Raised
$280.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Worg Pharmaceuticals operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series D Extension round in December 2025.
Worg Pharmaceuticals is a biopharmaceutical company that develops next-generation specific immunotherapies for allergic and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Worg Pharmaceuticals Comparables
Compare Worg Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Imcyse | 78% | |
| Inmunotek | 76% | |
| Aravax | 76% |
For institutional investors. Book with your work email.
Worg Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D Extension | Dec 19, 2025 | ||||
| Series D | Nov 20, 2024 | ||||
| Series C | Jul 11, 2023 | ||||
| Series B | Sep 15, 2022 | ||||
| Series A | Jan 18, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Worg Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CITIC Securities | Series B |
| Kaitai Capital | Series A, Series B |
| Junson Capital | Series B |
| Lapam Capital | Series B |
| DT Capital Partners | Series C |
| Mingfeng Capital | Series D Extension |
| PICC Capital Equity Investment Co., Ltd. | Series D, Series D Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 8, 2026
Monthly visitors grew 40% MoM.
- Dec 19, 2025
$42.2M round led by PICC Capital and LongRiver Investments.
For institutional investors. Book with your work email.
Worg Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Worg Pharmaceuticals's valuation, stock price, and market status.
Is Worg Pharmaceuticals a public or private company?
Worg Pharmaceuticals is a private company.
What is the current stock price of Worg Pharmaceuticals?
Worg Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Worg Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Worg Pharmaceuticals worth (valuation)?
Valuation information for Worg Pharmaceuticals is not publicly available.
Can I buy Worg Pharmaceuticals stock?
Worg Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Worg Pharmaceuticals's last funding round?
Worg Pharmaceuticals's most recent funding round was Series D Extension on December 19, 2025.
Who are the main investors in Worg Pharmaceuticals?
Key investors in Worg Pharmaceuticals include PICC Capital Equity Investment Co., Ltd., LongRiver Investments.
Will Worg Pharmaceuticals IPO soon?
No public IPO plans have been announced for Worg Pharmaceuticals.
How can I track Worg Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Worg Pharmaceuticals's shares on secondary markets.